近期，曾一度被炒至1600元一粒的中药名贵药品片仔癀，在部分渠道竟以350元的价格甩卖，引发市场广泛关注。片仔癀作为国家级非物质文化遗产，素有“药中茅台”之称，因其稀缺性和传统疗效，长期被视为收藏与投资标的。过去几年，受炒作、囤货及供需失衡影响，其价格屡创新高。然而，随着监管加强、市场理性回归以及消费者对高价保健品态度转变，片仔癀价格大幅回落。目前，官方指导价约为760元/粒，而部分电商平台或经销商为去库存，甚至以低于成本价促销。专家指出，这种价格波动反映出中药材市场过度金融化的风险，也提醒消费者应理性看待其药用价值，而非盲目跟风投资。长远来看，片仔癀应回归药品本质，依靠临床疗效和品牌信誉赢得市场，而非依赖投机炒作维持高价。
Recently, Pien Tze Huang—a renowned and expensive traditional Chinese medicine once speculated up to 1,600 RMB per pill—is now being sold at steep discounts of around 350 RMB in some channels, drawing widespread public attention. Recognized as a national intangible cultural heritage, Pien Tze Huang has long been dubbed the ‘Moutai of medicine’ due to its scarcity and reputed therapeutic effects, making it a popular item for both collection and investment. In recent years, prices soared amid market speculation, hoarding, and supply-demand imbalances. However, stricter regulatory oversight, a return to market rationality, and shifting consumer attitudes toward overpriced health products have led to a significant price correction. The official recommended retail price currently stands at approximately 760 RMB per pill, yet some e-commerce platforms and distributors are offering deep discounts—sometimes even below cost—to clear inventory. Experts warn that such volatility highlights the risks of excessive financialization in the traditional Chinese medicine market and urge consumers to focus on its genuine medicinal value rather than treating it as an investment vehicle. In the long run, Pien Tze Huang should return to its core identity as a medicine, relying on clinical efficacy and brand trust—not speculative hype—to sustain its market position.
原创文章，作者：admin，如若转载，请注明出处：https://ktez.cn/1368.html